Day: November 19, 2021

BATON ROUGE, La., Nov. 19, 2021 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the Stephens Annual Investment Conference on December 3rd at 10:00 am Eastern. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com. About Amedisys: Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is...

Enrolled and dosed last patient in the expansion stage of Part A (1st line non-small cell lung cancer (NSCLC)) needed to complete recruitment into all cohorts of the TACTI-002 study Interim data from Part C (2nd line head & neck squamous cell carcinoma (HNSCC) patients) presented at SITC 2021 Additional data from TACTI-002 expected to be reported in H1 calendar year 2022SYDNEY, AUSTRALIA, Nov. 19, 2021 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the last patient has been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study (also designated KEYNOTE-798). The Company announced that the TACTI-002 study has completed recruitment...

CHICAGO and TORONTO, Nov. 19, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, announced today that the Company’s Wesana Clinics business segment has surpassed 4,000 administered ketamine treatments for major depressive disorder, anxiety, PTSD, and addiction since inception. Daniel Carcillo, CEO of Wesana Health commented, “This is a significant achievement for Wesana Clinics. There is an urgent need for innovative and effective treatments to combat the current budding epidemics of suicide, addiction, anxiety, and depression. We continue to believe that Wesana’s clinical network remains at the forefront of mental health advancements while maintaining a strong foundation in traditional psychiatric care.” Wesana’s psychiatrist-led clinical...

To Nasdaq Copenhagen Nykredit Realkredit A/S – Extraordinary General Meeting on 19 November 2021 At the Extraordinary General Meeting of Nykredit Realkredit A/S held on Friday 19 November 2021, a resolution passed by the Board of Directors to distribute dividend of DKK 2.6 billion was approved. Copenhagen, 19 November 2021 Nykredit Realkredit A/SBoard of Directors ContactIf you have any questions, please contact Press Relations, tel +45 20 37 28 69.AttachmentExtraordinary_General_Meeting_On_November_19_2021_Nykredit_Realkredit_A_S_2021_11_19_UK

BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a virtual fireside chat at the Stephens Annual Investment Conference on November 29, 2021 at 12:00 pm ET. Dr. Tang will also speak in a virtual fireside chat at the Evercore 4th Annual HealthConx Virtual Conference on December 1, 2021 at 1:50 pm ET. The conferences will be simultaneously webcast over the Internet. Live webcasts and replays of the presentations can be accessed by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. Replays of the webcasts will be available on OraSure Technologies’...

Company reports 90% lithium recovery and projects up to 50% lower costs VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) — Medaro Mining Corp. (CSE: MEDA) (OTC: MEDAF) (FWB: 1ZY) (“Medaro” or the “Company”), a multi-faceted mineral explorer and joint venture (JV) partner with Global Lithium Extraction Technologies Inc., is pleased to provide an update regarding the venture’s innovative clean technology aimed at cost-effectively extracting lithium from spodumene. The JV’s technology, as previously announced, is a thermochemical solvent extraction technique designed to rapidly manufacture lithium carbonate (Li2CO3) and/or lithium hydroxide (LiOH) from a variety of spodumene (LiAlSi2O6-rich) concentrates. The method is modular and highly scalable, thereby enabling a small “factory footprint” and holds the potential to significantly...

TORONTO, Nov. 19, 2021 (GLOBE NEWSWIRE) — Consolidated Uranium Inc. (“CUR”, the “Company” or “Consolidated Uranium”) (TSXV: CUR) (OTCQB: CURUF) is pleased to announce that its common shares listed on the OTCQB under the symbol “CURUF” are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered to be “DTC eligible”. The electronic method of clearing securities through the DTC allows for cost-effective clearing and guaranteed settlement, simplifying and accelerating the settlement process...

VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency (“UK MHRA”). The scientific advice meeting was related to the Company’s planned Phase 1/2a stroke study with AP-188 (“N,N-dimethyltryptamine” or “DMT”), a known psychedelic compound that is part of the tryptamine family. As a result of the meeting, the Company plans to file a Clinical Trial Authorisation (CTA) application for the study as soon as possible. In addition, and based on the feedback received, the Company is also considering focussing on...

HINGHAM, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY® Robotic System. Globally, the Company now has 46 patents issued/allowed and 24 pending patent applications and is continuously submitting applications to protect its Intellectual Property. “We believe that the U.S. is the largest and most significant market opportunity for the LIBERTY® Robotic System, and with two allowances in a few short months, it clearly demonstrates the innovative nature of our technology,” commented Harel Gadot, CEO, President and Chairman. “2022 is poised to be an important year for the LIBERTY® Robotic System. It’s critical that we approach this period knowing...